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Abstract
Background: Multidrug resistance-associated protein-1 (MRP1) protects against oxidative stress and toxic compounds 
generated by cigarette smoking, which is the main risk factor for chronic obstructive pulmonary disease (COPD). We 
have previously shown that single nucleotide polymorphisms (SNPs) in MRP1 significantly associate with level of FEV1 in 
two independent population based cohorts. The aim of our study was to assess the associations of MRP1 SNPs with 
FEV1 level, MRP1 protein levels and inflammatory markers in bronchial biopsies and sputum of COPD patients.
Methods: Five SNPs (rs212093, rs4148382, rs504348, rs4781699, rs35621) in MRP1 were genotyped in 110 COPD 
patients. The effects of MRP1 SNPs were analyzed using linear regression models.
Results: One SNP, rs212093 was significantly associated with a higher FEV1 level and less airway wall inflammation. 
Another SNP, rs4148382 was significantly associated with a lower FEV1 level, higher number of inflammatory cells in 
induced sputum and with a higher MRP1 protein level in bronchial biopsies.
Conclusions: This is the first study linking MRP1 SNPs with lung function and inflammatory markers in COPD patients, 
suggesting a role of MRP1 SNPs in the severity of COPD in addition to their association with MRP1 protein level in 
bronchial biopsies.
Background
Chronic obstructive pulmonary disease (COPD) is an
inflammatory lung disease associated with an influx of
neutrophils, macrophages and CD8+ T-lymphocytes in
the airways and lung tissue[1]. Smoking generates oxida-
tive stress resulting from an oxidant - antioxidant imbal-
ance, and oxidative stress markers are increased in
airspaces, blood and urine of smokers and COPD
patients[2]. Oxidative stress can be reduced by members
of the ATP-binding cassette (ABC) superfamily of trans-
porters. One such a transporter is multidrug resistance-
associated protein-1, MRP1, (official name ABCC1, ABC
subfamily C, member 1) that plays an important role in
normal lung physiology by protecting against toxic xeno-
biotics and endogenous metabolites[3].
MRP1 was first detected in small cell lung cancer. It has
been shown to be highly expressed in the normal human
lung [4,5] and particularly at the basolateral side of
human bronchial epithelial cells[6]. Interestingly, we have
previously shown that MRP1 is less expressed in bron-
chial epithelium of COPD patients compared to healthy
subjects[7]. Mrp1/Mdr1a/1b triple knock-out mice had a
poor ability for smoke-induced IL-8 production com-
pared with wild type mice, which associated with almost
complete absence of inflammatory cells in response to
cigarette smoke[8]. An additional study demonstrated
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that cigarette smoke extract inhibits MRP1 activity in
bronchial epithelial cells in vitro[9]. Thus there is a clear
role for MRP1 in COPD.
A total of 51 single nucleotide polymorphisms (SNPs)
with a minor allele frequency (MAF) > 5% are required to
tag the entire MRP1  gene in Caucasians[10]. We have
shown that two SNPs in MRP1  significantly associate
with a lower or higher level of FEV1 in two independent
population-based cohorts. Two additional SNPs had a
significant effect of the same, negative magnitude on the
level or decline of FEV1. One SNP was a significant pre-
dictor of COPD in the general population [11].
So far , no study has focused on the relation between
MRP1  polymorphisms and the level of lung function,
inflammatory markers and MRP1 protein in lung tissue
of individuals with established COPD. We had the unique
opportunity to do so in a recently finished, two center
trial in COPD that amongst others studies inflammatory
markers in bronchial biopsies and induced sputum[12].
Furthermore, we assessed whether MRP1 protein levels
in bronchial biopsies of COPD patients are associated
with MRP1 SNPs.
Methods
Study populations
COPD patients
We included 114 patients with COPD who participated in
a two-center trial (Groningen Leiden Universities and
Corticosteroids in Obstructive Lung Disease; GLUCOLD
study). Patient characteristics and methods have been
described in detail previously[12]. In brief, all patients
had irreversible airflow limitation and chronic respira-
tory symptoms[13]. Included patients had neither used a
course of oral steroids during the previous 3 months, nor
maintenance treatment with inhaled or oral steroids dur-
ing the previous 6 months. They were current or ex-
smokers with a smoking history of ≥10 packyears, aged
between 45 and 75 years without a history of asthma. The
study was approved by the medical ethics committees of
the University Medical Centers of Leiden and Groningen.
All patients gave their written informed consent.
Controls
T o  v e r i f y  t h e  d i f f e r e n c e s  o f  M R P 1  l e v e l s  i n  b r o n c h i a l
biopsies between COPD patients and healthy subjects, we
included 37 subjects as controls, of which 28 were previ-
ously recruited in order to participate in a smoking cessa-
tion program[14]. They were symptomatic and
asymptomatic smokers according to the ATS-ERS
(American Thoracic Society-European Respiratory Soci-
ety) guidelines [15] and met the following criteria: 45-75
years of age, >10 pack years of smoking, FEV1/FVC pre
and post bronchodilator > 70%, no use of inhaled or oral
corticosteroids in the previous 6 months, no sign of
atopy, no respiratory tract infections one month prior to
the study and none of the participants had any co-mor-
bidity[14]. The remaining 9 subjects were included as
controls with an FEV1/FVC pre and post bronchodilator
> 70% and FEV1 >80% predicted.
We used an additional control group from the general
population-based cohort (Doetinchem) [16] to check for
the differences in genotype distributions between COPD
patients and general population (Additional file 1).
Clinical characteristics
Lung function and reversibility to salbutamol were mea-
sured as described previously for COPD patients [12] and
for controls[14].
Sputum induction and processing were performed as
described previously [12] according to a validated tech-
nique[17]. Details on biopsy processing, immunohistol-
ogy and analysis have been published previously[18]. In
brief, we collected the two best morphological biopsies
out of four paraffin embedded biopsies per patient and
used specific antibodies against T lymphocytes (CD3,
CD4 and CD8), macrophages (CD68), neutrophil elastase
(NE), mast cell tryptase (AA1) and eosinophils (EG2)
(Additional file 1).
Selection of the MRP1 tagging SNPs and genotyping
We selected SNPs based on our previous results showing
a significant association of 5 MRP1  SNPs (rs212093,
rs4148382, rs35621, rs4781699 and rs504348) with the
FEV1 level and/or annual FEV1 change in two indepen-
dent population-based cohorts [11]. The rs504348 SNP
results in a significant increase in MRP1 promoter activ-
ity in vitro[19]. Genotyping was performed by K-Biosci-
ence (UK) using their patent-protected competitive allele
specific PCR system (KASPar).
Biopsies and immunohistochemistry on bronchial biopsies 
from COPD patients and controls
Details on bronchial biopsy collection and processing are
described in the data supplement. Four paraffin-embed-
ded biopsies were cut in 4 μm thick sections and haema-
toxylin/eosin staining was used for evaluation and
selection of the best morphological biopsy per subject for
analysis (without crush artefacts, large blood clots, or
only epithelial scrapings). The staining was performed on
one paraffin section of 4 μm per subject with monoclonal
antibody MRPr1 for MRP1 (Santa Cruz, California,
USA). Details on immunohistochemical staining are
described in Additional file 1.
Evaluation of immunohistochemistry on bronchial biopsies 
from COPD patients and controls
Evaluation of different types of epithelium was performed
separately (i.e. basal epithelium, squamous metaplasia,
intact epithelium). For the current study, intact bronchial
epithelium was selected for analysis.Budulac et al. Respiratory Research 2010, 11:60
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MRP1 protein was scored for staining intensity in intact
epithelium of bronchial biopsies with a semi quantitative
score: 0 = no staining; 1 = weak; 2 = moderate; 3 = strong.
MRP1 intensity scores for intact epithelium were avail-
able from 80 bronchial biopsies of subjects with COPD
and 26 bronchial biopsies of controls. Due to the fact that
there were only 3 individuals with no immunohistochem-
ical expression of MRP1, the MRP1 intensity was categor-
ised in 3 groups: 1 = weak staining, 2 = moderate staining
and 3 = strong staining. Two observers (S.B. and W.T.)
performed all evaluations of bronchial biopsies individu-
ally, in a blinded manner. Most sections stained variable
for MRP1 in epithelium and parts with the most intense
staining were evaluated for scoring.
Statistics
Numbers of inflammatory cells in bronchial biopsies and
induced sputum were log transformed to achieve a nor-
mal distribution. Linear regression analyses were per-
formed to investigate the association of MRP1 SNPs with
FEV1 level and inflammatory cells (natural logarithm) in
bronchial biopsies and induced sputum. Independent
variables included in the model were age, gender, height,
packyears and genotypes. To assess the effect of SNPs on
FEV1 level and cell numbers in bronchial biopsies and
induced sputum we used the following genetic models:
• General: heterozygote and homozygote variants
coded separately as dummy variables and compared
to the homozygote wild type
• Dominant: heterozygote and homozygote variants
pooled and compared to the homozygote wild type
Differences in MRP1 staining intensity between biop-
s i e s  o f  C O P D  p a t i e n t s  a n d  c o n t r o l s  a n d  a c c o r d i n g  t o
MRP1 SNPs were analyzed using Chi-square tests. Analy-
ses were performed using SPSS version 16.0 for Windows
and values of p < 0.05 (tested 2-sided) were considered
statistically significant.
Results
The clinical characteristics of COPD patients and con-
trols are presented in Table 1.
DNA was available from 110 out of 114 COPD patients
and from 37 controls. All 5 MRP1 SNPs were in Hardy
Weinberg Equilibrium (HWE, p > 0.05) and were not
highly correlated with each other (the highest r2 in our
population is 0.34) (See figure S1 in Additional file 2).
There were no significant differences in genotype distri-
butions between the COPD patients and the general pop-
ulation-based control cohort (Additional file 1). Likewise,
there were no significant differences in genotype distri-
butions between the COPD patients and controls (Table
2).
Table 3 shows the number and the percentage of
inflammatory cells in bronchial biopsies and induced
sputum from the COPD patients.
MRP1 SNPs and FEV1 level in COPD patients
In a general model, individuals who were homozygote
mutant (GG) for rs212093 had a significantly higher FEV1
than wild type (AA) individuals, as reflected by a regres-
sion coefficient B value (95% CI, confidence interval) of
222 ml (48 ml to 396 ml); p = 0.013. Heterozygote (GA)
individuals for rs4148382 had a significantly lower FEV1
than wild type (GG) individuals (-215 ml (-356 ml to -75
ml); p = 0.003). None of the other 3 SNPs (rs504348,
rs4781699 and rs35621) was significantly associated with
the FEV1 level (Figure 1). Additional adjustment for cur-
rent smoking status did not change the size or signifi-
cance of the effect estimates of the genotypes on level of
FEV1.
MRP1 SNPs and inflammatory cells in bronchial biopsies in 
COPD patients
Homozygote mutant (GG) individuals for rs212093 had a
significantly lower number of plasma cells (-0.72 (-1.27 to
-0.18); p = 0.01), neutrophils (-0.63 (-1.16 to -0.09); p =
0.02) and macrophages (-0.61(-1.07 to -0.15); p = 0.01) in
bronchial biopsies than wild type (AA) individuals (Fig-
ures 2a, b and 2c, respectively). Individuals who were
heterozygote (AG) for rs212093 had lower numbers of
mast cells than wild type (AA) individuals (-0.25 (-0.47 to
-0.03); p = 0.02) (Figure 2d).
Minor allele carriers (GT/TT) for rs4781699 had signif-
icantly lower numbers of macrophages (-0.34 (-0.67 to -
0.02); p = 0.04) than wild type (GG) individuals (Figure 3).
The genotypes for the other two SNPs (rs4148382 and
rs35621) were not significantly associated with any of the
inflammatory cells in the bronchial biopsies.
MRP1 SNPs and inflammatory cells in sputum in COPD 
patients
Heterozygote (GA) individuals for rs4148382 had a sig-
nificantly higher total cell count (0.59 (0.11 to 1.07) p =
0.01) and neutrophils (0.61 (0.06 to 1.16); p = 0.03) in spu-
tum compared to wild type (GG) individuals. None of the
other SNPs was significantly associated with inflamma-
tory cells in sputum.
Additional adjustment for current smoking status did
not change the size or significance of the effect estimates
of the genotypes on inflammatory cells in bronchial biop-
sies and in induced sputum.
Detailed data on the MRP1 genotypes and inflamma-
tory cells in bronchial biopsies and induced sputum are
presented in the Additional file 1.Budulac et al. Respiratory Research 2010, 11:60
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MRP1 protein levels in COPD patients and controls
There were no significant differences in MRP1 protein
levels between COPD patients and controls.
Heterozygote (GA) individuals for rs4148382 had a sig-
nificantly higher MRP1 protein level than wild type (GG)
individuals in COPD patients (p = 0.026) (Figure 4a) and
in the control group minor allele carriers (GA/AA) for
rs4148382 had a significantly higher MRP1 protein level
than wild type (GG) individuals (p = 0.037) (Figure 4b).
Minor allele carriers (GT/TT) for rs4781699 had signif-
icantly lower MRP1 protein level than wild type (GG)
individuals in COPD patients (p = 0.036) (Figure 4c), but
there was no significant difference in MRP1 protein level
in the control group (Figure 4d).
None of the other 3 SNPs (rs212093, rs504348 and
rs35621) associated significantly with MRP1 protein lev-
els. Levels of MRP1 were not related to lung function
parameters, inflammatory cells in bronchial biopsies or
number of packyears.
Discussion
This is the first study linking MRP1 SNPs with the sever-
ity of COPD and additionally with the intensity of MRP1
staining in bronchial biopsies. Our results suggest a role
of MRP1 in COPD severity, as indicated by the associa-
tions of rs212093 genotypes with a higher level of FEV1
and less inflammatory cells in bronchial biopsies. Addi-
tionally, the SNPs rs504348 and rs4781699 were associ-
ated with less airway wall inflammation and rs4148382
with a lower FEV1 level and increased sputum cell num-
bers. Moreover, the before mentioned SNPs rs4148382
and rs4781699 were associated with respectively higher
and lower levels of MRP1 protein in bronchial biopsies of
COPD patients (see summary of the results in Figure 5).
Since first described in 1992 [4], a fair amount of data
on the structure, substrate, function, and regulation of
this transporter has been gathered. MRP1 is a member of
the human ATP-binding cassette superfamily of trans-
porters which regulates the traffic of molecules across
cell membranes. The MRP1 pump confers resistance to
several chemotherapeutic agents including vincristine,
daunorubicin and methotrexate[20,21]. In addition to
protecting cells within the body against drugs, environ-
mental toxins and heavy metals, MRP1 has been sug-
gested to be involved in the cellular oxidative defence
system and inflammation [22,23], both being important
in COPD development and progression.
We showed that the MRP1  polymorphism rs212093
was significantly associated with a higher FEV1 level. In
line with this, rs212093 SNP was associated with lower
numbers of plasma cells, macrophages, neutrophils and
mast cells in bronchial biopsies, cells implicated in COPD
previously. Increased numbers of neutrophils have been
reported in bronchial biopsies of smokers with airflow
Table 1: Clinical characteristics of COPD patients and controls with airway biopsy available.
COPD patients (n = 114) Controls (n = 37)
Males, n (%) 99 (86.8) 16 (43.2)
Age (years) 61.6 ± 7.7 52.3 ± 5.5
Height (cm) 175.5 ± 7.8 172.8 ± 10
Packyears¶ 41.8 (31.2 - 54.7) 25.4 (20.2-35.0)
Current smoker, n (%) 72 (63.2) 30 (81.1)
FEV1/FVC (%) 49.5 ± 8.8 77.2 ± 6.1
FEV1 (L) 1.8 ± 0.4 3.2 ± 0.8
FEV1 % pred.* 56 ± 10 100 ± 14
MRP1 level #, n 80 26
Data are presented as mean ± standard deviation or ¶ median (25th - 75th percentile); FEV1 = forced expiratory volume in one second; FEV1/
FVC = FEV1/forced vital capacity; * % pred. = percentage of predicted value; # refers to the number of individuals having bronchial biopsies 
with available MRP1 levels of intensity; MRP1 = multidrug resistance-associated protein-1Budulac et al. Respiratory Research 2010, 11:60
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limitation, an increase that was associated with a lower
FEV1[24]. Neutrophils and macrophages release prote-
olytic enzymes and generate oxidants, which cause tissue
d a m a g e  a s  w e l l  as  cyt o k i n e s  a n d  c h e m o k i n e s  t h a t  c a n
potentiate inflammation and trigger an immune
response. W e previously reported a larger number of B
lymphocytes in bronchial biopsies of patients with COPD
than in controls without airflow limitation[25]. Further-
more, epithelial cells of smokers with COPD contain
higher macrophage and mast cell numbers than smokers
without COPD[26]. In a triple knock-out mouse model,
we previously demonstrated that the inflammatory
response to inhalation of cigarette smoke is reduced
when MRP1 is absent[8]. Linking previously reported
i n c r e a s e d  a i r w a y  w a l l  i n f l a m m a t i o n  i n  C O P D  w i t h
genetic variants of MRP1 we found rs212093 to be associ-
ated with lower numbers of inflammatory cells in bron-
chial biopsies, therefore, this SNP might play a protective
role in COPD. This SNP located in 3'region is known to
be in complete linkage disequilibrium with rs129081
located in the 3' untranslated region [10] and therefore
this polymorphism might be involved in the regulation of
MRP1 mRNA stability[11].
One could raise the issue of multiple testing and that we
should have adjusted for this in our analyses, but we feel
that applying a sequential (classical) Bonferroni correc-
tion is not appropriate in the current dataset for a num-
ber of reasons[27]. Firstly, our choice for the current
Table 2: Prevalence of MRP1 SNPs in COPD patients and controls.
COPD patients 
n = 110 (%)
Controls n = 37 (%) p value
rs212093 AA 37 (33.9) 8 (25.0) 0.55
AG 50 (45.9) 18 (56.2)
GG 22 (20,2) 6 (18.8)
rs4148382 GG 83 (76.1) 29 (82.8) 0.12
GA 26 (23.9) 5 (14.3)
AA - 1 (2.9)
rs504348 CC 78 (72.2) 22 (71.0) 0.23
CG 27 (25.0) 6 (19.3)
GG 3 (2.8) 3 (9.7)
rs4781699 GG 58 (52.7) 21 (61.8) 0.47
GT 45 (40.9) 10 (29.4)
TT 7 (6.4) 3 (8.8)
rs35621 CC 89 (80.9) 30 (85.7) 0.74
CT 20 (18.2) 5 (14.3)
TT 1 (0.9) -
Different numbers for the SNP genotypes are due to missing genotype data
SNP = single nucleotide polymorphism; MRP1 = multidrug resistance-associated protein-1Budulac et al. Respiratory Research 2010, 11:60
http://respiratory-research.com/content/11/1/60
Page 6 of 11
study was explicitly driven by our previous findings, sug-
gesting that there might be associations between MRP1
SNPs and COPD severity. Thus, we explicitly hypothe-
sized on the main outcome variables on forehand. Sec-
ondly, a Bonferroni correction would not take into
account the potential clustering of outcome variables,
which might occur jointly at high or low levels, e.g. a
Pearson's correlation coefficient r = 0.79 for macrophages
and lymphocytes in induced sputum, or are defined as
each others ratios[27]. This suggests one might preferen-
tially test a cluster of outcome variables as "one outcome
variable" rather than test all variables separately.
It has been shown previously that higher neutrophil
percentages in induced sputum correlate with lower FEV1
levels [28], therefore it is of interest that rs4148382,
located in 3'region of MRP1, is associated significantly
with higher total cells counts and neutrophils in induced
sputum and lower FEV1 level. The association with total
cell counts might be driven by the neutrophils which rep-
resent 72% of the total cells in induced sputum. The func-
tional consequence of this particular SNP is not known so
far and it is not known whether any functional polymor-
phism is in linkage disequilibrium with it. This polymor-
phism is located closely to the 5'end of the MRP6 which
maps also on chromosome 16. However, MRP6 mRNA is
Table 3: The number of inflammatory cells in bronchial biopsies and induced sputum of COPD patients
Bronchial biopsies Absolute numbers per 0.1 mm2 sub-epithe-
lial area
CD3 123.5 (69.2 - 182.5)
CD4 48.0 (27.7 - 72.0)
CD8 21.5 (11.0 - 37.2)
Plasma cells 8.5 (3.5 - 14.5)
Mast cells 26.5 (19.0 - 34.5)
Macrophages 8.5 (4.5 - 13.0)
Neutrophils 4.0 (2.0 - 8.4)
Eosinophils 1.5 (0.5 - 4.2)
Induced sputum Absolute numbers (104/ml) Percentage (%)
Total cell count* 139.7 (77.9 - 311.3)
Neutrophils 101.6 (46.8 - 228.5) 72.8 (59.9 - 81.7)
Macrophages 31.1 (17.9 - 61.1) 22.1 (14.8 - 33.2)
Eosinophils 1.3 (0.4 - 4.5) 1.1 (0.3 - 2.2)
Lymphocytes 2.2 (1.1 - 6.8) 1.7 (1.2 - 2.3)
Epithelial cells 1.4 (0.6 - 3.4) 1.0 (0.3 - 2.3)
Data are presented as median (25th - 75th percentile)
*Total cell count refers to the number of non-squamous cells in induced sputumBudulac et al. Respiratory Research 2010, 11:60
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moderately present in human lung extracts [29] and
highly expressed in the liver and kidney [6], which might
suggest indeed that the effect of this particular SNP is
within MRP1 and not MRP6. How this SNP functionally
contributes to COPD severity has to be further unrav-
elled in future studies.
The observed effects in the current study appear to be
opposite to previous findings in the same general popula-
tion as described by Siedlinski et al[11]. In the current
study, which extends the previous findings, we observed
that rs4148382 associated with a lower FEV1  level in
COPD patients, whereas in the general population from
the Doetinchem study rs4148382 associated with a higher
FEV1 level [11]. With respect to these findings it is worth
mentioning that the present study was not designed to
compare the direction or magnitude of effect estimates
between the COPD patients and general population with
respect to FEV1 and genetic factors. The opposite effects
are likely due to the fact that we selected a COPD subset
of the Doetinchem general population for the current
study by matching on the clinical characteristics age,
number of packyears and FEV1/FVC<70%. Although
both groups had almost the same number of packyears
(median 25th - 75th percentile) (40 (34.1 - 48.7) vs. 41.8
(31.2 -54.7)), the matched COPD subset in the general
population had a higher lung function (mean FEV1 % pre-
dicted (SD) = 79.7 (13.4)) than our current COPD
patients (49.5 (8.8)). This suggests that the COPD subset
of subjects from the Doetinchem study who, fulfilled the
GOLD criteria of COPD, might be less susceptible to cig-
arette smoke and COPD development. Therefore, the
patients included in the current study with established
COPD were probably not comparable with the heavy
smokers from the general population based control
cohort (Doetinchem).
Additionally, we have calculated the haplotypes of
MRP1  and assessed the effects of these haplotypes on
FEV1 level and inflammatory cells in bronchial biopsies
and induced sputum. We observed that the effects of
MRP1 haplotypes are due to the specific SNP constituting
these haplotypes, and therefore didn't add new informa-
tion. Details on the MRP1 haplotypes are presented in the
Additional file 1.
Decreased or increased functional MRP1 expression
may have a high impact on development and/or progres-
sion of lung diseases and protection against air pollution
and inhaled toxic compounds such as present in cigarette
smoke[6,7,30]. One of our earlier studies showed that the
MRP1 intensity in bronchial biopsies of COPD patients
was lower compared to healthy individuals[7]. How can
w e  r e c o n c i l e  t h i s  w i t h  o u r  c u r r e n t  f i n d i n g s  o f  M R P 1
staining in COPD patients and controls? One option is
Figure 1 Estimated effects of MRP1 genotypes on level of FEV1 in COPD patients. FEV1 = forced expiratory volume in one second. N= Number 
of individuals. Squares represent the regression coefficient (B) and vertical bars represent 95% confidence interval (CI). Wild type was set to zero as the 
reference category. The analyses are adjusted for age, gender, height and packyears.Budulac et al. Respiratory Research 2010, 11:60
http://respiratory-research.com/content/11/1/60
Page 8 of 11
that this might be due to differences in staining between
paraffin and frozen biopsies[31]. More important, it
might be due to underlying differences of MRP1 genotyp-
ing distribution in the two populations. It appeared that
the previous low intensity of MRP1 staining was driven
by wild type individuals [7] and if we would have known
this at that time, it might have had a different impact on
t h e  i n t e r p r e t a t i o n  o f  t h e  r e s u l t s .  M R P 1  i s  a n  e s s e n t i a l
pump for glutathione (GSH) - conjugates such as the
inflammatory mediator leukotriene C4 (LTC4) as well as
substrates in the presence of GSH (i.e. glutathione disul-
phide, GSSG) [32], thereby decreasing intracellular con-
centrations of toxic compounds. Given the rarity of
homozygote mutant (AA) individuals for rs4148382 all
the conclusions about this SNP are drawn based on the
heterozygote (GA) individuals in COPD patients. It might
be that in particular individuals who are heterozygote for
rs4148382 SNP can have a locally high MRP1 protein
level which therefore might lead to more severe inflam-
mation at that site. Clearly, further research needs to
investigate this approach in a larger sample of subjects
with or without COPD.
Conclusions
In conclusion, our study is the first to demonstrate that
MRP1 plays a role in COPD severity, given the associa-
tion of polymorphisms in MRP1 with airway wall inflam-
mation, the level of lung function and moreover MRP1
protein levels in subjects with established COPD. This is
an important step forward linking MRP1 polymorphisms
with the pathophysiology of COPD.
Figure 2 Estimated effects of MRP1 genotypes on inflammatory cells in bronchial biopsies of COPD patients. 2a: Number of plasma cells ac-
cording to rs212093 genotype. 2b: Number of neutrophils according to rs212093 genotype. 2c: Number of mast cells according to rs212093 genotype. 
2d: Number of macrophages according to for rs212093 genotype.
Figure 3 Estimated effects of MRP1 genotypes on inflammatory 
cells in bronchial biopsies of COPD patients. Number of mac-
rophages according to rs4781699 genotype. N = number of individu-
als. Data are presented as natural logarithm of each type of cells in 
bronchial biopsies. Different numbers for the SNP genotypes are due 
to missing data on genotype or inflammatory cells. Squares represent 
the regression coefficient (B) and vertical bars the 95% confidence in-
terval (CI). Wild type was set to zero as the reference category. The anal-
yses are adjusted for age, gender and packyears.Budulac et al. Respiratory Research 2010, 11:60
http://respiratory-research.com/content/11/1/60
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Figure 4 MRP1 SNPs and MRP1 protein levels of COPD patients and controls. 4a: MRP1 protein levels according to rs4148382 genotype in COPD 
patients. 4b: MRP1 protein levels according to rs4148382 genotype in controls. 4c: MRP1 protein levels according to rs4781699 genotype in COPD 
patients. 4d: MRP1 protein levels according to rs4781699 genotype in controls. N= number of individuals.
Figure 5 Summary of MRP1 SNPs' associations for COPD patients. FEV1 = forced expiratory volume in one second; MRP1 = multidrug resistance-
associated protein-1; ￿ = positive association; ￿ = negative association; - = no association.Budulac et al. Respiratory Research 2010, 11:60
http://respiratory-research.com/content/11/1/60
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